Showing results (31-40 of 296) with videos related to

Sort By:
Pageof 30
European Journal of Cancer (Oxford, England : 1990)|June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international surveyXavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
European Urology|July 24, 2003
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892)Laurence Collette, Theo M de Reijke, Fritz H Schröder, et al.
Plos Computational Biology|November 21, 2015
A Dual Model for Prioritizing Cancer Mutations in the Non-coding Genome Based on Germline and Somatic EventsJia Li, Marie-Anne Poursat, Damien Drubay, et al.
British Journal of Haematology|April 9, 2020
A new efficient tool for non-invasive diagnosis of fetomaternal platelet antigen incompatibilityYasmine Ouzegdouh Mammasse, Christophe Chenet, Damien Drubay, et al.
Contemporary Clinical Trials Communications|July 25, 2019
An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction errorShaima Belhechmi, Stefan Michiels, Xavier Paoletti, et al.
Journal of Ovarian Research|July 22, 2024
External validation of Standardized KELIM and platinum-resistant recurrence scores in patients with advanced epithelial ovarian cancerNina Oufkir, Roman Rouzier, Xavier Paoletti, et al.
Clinical Trials (London, England)|September 21, 2019
Sequential or combined designs for Phase I/II clinical trials? A simulation studyCaroline Rossoni, Aurélie Bardet, Birgit Geoerger, et al.
Contemporary Clinical Trials|January 31, 2016
Innovations for phase I dose-finding designs in pediatric oncology clinical trialsAdelaide Doussau, Birgit Geoerger, Irene Jiménez, et al.
Pharmaceutical Statistics|June 18, 2026
Early Phase Dose-Finding Designs for CAR-T Cell TherapiesWeishi Chen, Pavel Mozgunov, Jimmy Mullaert, et al.
Pageof 30